Peter Maag, PhD, Chief Executive Officer and President
Dr. Maag has over 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining CareDx, Dr. Maag was President of Novartis Diagnostics based in Emeryville, California. He headed the expansion of the unit with worldwide growth in its blood screening business and established new ventures in molecular diagnostics. Dr. Maag also led one of Novartis’ key affiliates as Country President, Germany, and lived in a dynamically-growing and emerging market as Country President, Korea. At Novartis headquarters in Switzerland, he helped launch the Infectious Diseases franchise and served as the Head of Strategy for Novartis Pharmaceuticals. Prior to joining Novartis, Dr. Maag worked for 6 years at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Supporting various healthcare and high tech companies in their growth efforts, he holds board and advisory positions at Phoenix, MolecularMD, and Cobaltix. Dr. Maag studied pharmaceutical sciences in Heidelberg and London, and received his PhD from the University of Berlin, Germany.
Michael Bell, Chief Financial Officer
Michael Bell brings over 20 years of international finance and accounting experience. Michael is the former CFO of Metabiota, an infectious disease risk analytics company. Previously, he served as the CFO of Singulex, a clinical diagnostics company, and has held leadership and executive positions within Novartis, including tenure as the CFO of Novartis Diagnostics, a global provider of blood screening solutions. Previously, Michael worked in public accounting at Ernst & Young and Deloitte. Michael holds a Bachelor of Science degree in Mathematics with Computing from the University of Leicester in the United Kingdom, and is a Fellow of the Institute of Chartered Accountants in England & Wales.
Sasha King, Chief Commercial Officer
Sasha King brings over 10 years of diagnostics and genetic testing experience. Most recently she worked in companion diagnostics marketing at Genentech, and was a sales leader at Ariosa Diagnostics. While at Genentech, she worked on the launch of the first FDA approved cell free DNA test in oncology, the PD-L1 test launch, and the Foundation Medicine partnership. Sasha was an early member of the commercial team at Ariosa, a leader in the field of noninvasive prenatal testing (NIPT) which is now part of the Roche Group. She led the launch of their test into Asia Pacific and Canada. Sasha previously worked at Fletcher Spaght, a life science consulting and venture capital fund. Sasha received a bachelor of science in bioengineering from Massachusetts Institute of Technology and an MBA from Stanford Graduate School of Business.
Anders Karlsson, M.B.A., Chief International Business Officer
Mr. Karlsson joined CareDx in April 2016. Previously he served as the Chief Executive Officer of Allenex AB, a life sciences company that developed, manufactured, marketed and sold products for safer transplantation of blood, stem cells and organs. From 2009 to 2011, he served as the Chief Executive Officer of Olerup International AB, a global distributor of molecular diagnostic products and services. From 2008 to 2009, Mr. Karlsson served as the Chief Executive Officer of AbSorber AB, a biotech company that develops products for increasing the probability of transplantation success. Prior to that, Mr. Karlsson held positions of increasing responsibility at Novartis Pharmaceuticals in Sweden, including Head of Sales, Head of Sales and Marketing, and Country President for Novartis Norway.
Mr. Karlsson studied economics at the University of Jönköping and marketing management at IHM Business School Linköping in Sweden. Mr. Karlsson received his M.B.A. from the Henley Business School at the University of Reading, United Kingdom.
Mitchell J. Nelles, PhD, Chief Operating Officer
Dr. Mitch Nelles has more than 20 years of management and research and development experience in a variety of in vitro diagnostic (IVD) technology and business areas. Dr. Nelles joined CareDx from bioMerieux Inc, where he was Vice President of North America Research and Development and responsible for product development and project management for the bacteriology, molecular diagnostics, immunodiagnostics, and hemostasis business franchises. Prior to his work at bioMerieux, Dr. Nelles served as the Vice President of R&D at TriPath Oncology (TriPath Imaging) where he led the efforts to develop molecular-based products for the diagnosis and prognosis of breast and cervical cancer. Earlier in his career, Dr. Nelles held a variety of technical and managerial positions of increasing responsibility, including Vice President, Transfusion Medicine and Immunodiagnostic Assay R&D at Ortho Clinical Diagnostics (Johnson & Johnson) where he led the worldwide research and development activities in support of the blood screening, blood typing, immunodiagnostic, and RhoGAM business franchises. Dr. Nelles received his bachelor’s degree from Rutgers College in biological sciences, his PhD in immunology/biomedical sciences from the University of Texas, Health Sciences Center at Dallas (UTHSCD)/Southwestern Medical School, and completed postdoctoral training in immune regulation at Brandeis University.
Marissa Dixon, Vice President, Human Resources
Marissa Dixon has broad Human Resources experience in a range of high-growth, fast-paced industries. Over the last several years, she has specialized in the distinctive needs of the Biotechnology field.Prior to joining CareDx, Marissa served as the Vice President of Human Resources at Metabiota in San Francisco where her mission was to build an innovative Human Resources function and people programs to attract and retain high performing talent to the rapidly growing startup up focused on infectious disease data and analytics. Marissa has also held Senior HR Leadership roles in the SF Bay Area at DuPont Industrial Biosciences (formerly Genencor) and WageWorks. Marissa holds an M.S. in Human Resource Design and an M.A. in Psychology from Claremont Graduate University as well as an undergraduate degree in Social Sciences from Cal Poly San Luis Obispo.
Robert N. Woodward, PhD, Vice President, Research and Development
Dr. Robert Woodward has led research and development projects in transplant diagnostics and gene expression discovery for over 20 years. Most recently at CareDx he was responsible for the bioinformatics, biostatistics, and laboratory teams that developed and validated AlloSure, an application of cell-free DNA to solid organ transplantation. Earlier in his career, he initiated biomarker discovery efforts with BioCardia and XDx and subsequently led the laboratory development of AlloMap, a gene expression test that has become an integral component of precise patient care in heart transplantation. During a post-doctoral fellowship at the Gladstone Institutes and University of California San Francisco, Dr. Woodward developed unique methods for analysis of gene regulation in vivo to study atherosclerosis. Following a bachelor’s degree in biology from Missouri State University, Dr. Woodward earned his Ph.D. in physiology at the University of Missouri-Columbia where he described the effects of a new transcription factor in the coordinate regulation of gene expression in response to steroids.
James Yee, MD, PhD, Executive Vice President and Chief Medical Officer
Dr. James Yee brings more than 25 years of research and development experience. Most recently, Dr. Yee served as Vice President and Head of Development for Celera Genomics, where he built the development organization at Celera South San Francisco and led clinical research and therapeutic development activities for cancer and immune-mediated inflammatory diseases. Prior to his work at Celera, Dr. Yee served as Vice President of Clinical and Pre-Clinical Research for the Inflammatory and Viral Diseases Unit at Roche Pharmaceuticals. In this role, he led the team responsible for selecting and evaluating compounds for clinical drug development and oversaw groups responsible for toxicology, drug metabolism, pharmacokinetics, bioanalytical chemistry, analytical chemistry, formulations, regulatory affairs, project management, and clinical research. Earlier in his career, Dr. Yee held a variety of research and development positions of increasing responsibility at Syntex Corporation, including Vice President and Director of the Institute for Clinical Medicine. Dr. Yee received his bachelor’s degree from the University of California at Berkeley in electrical engineering and computer science. Dr. Yee went on to earn a PhD in biophysics at University of California at Berkeley. He attended the University of California, Los Angeles School of Medicine, where he earned his medical degree, and he is board certified in internal medicine.